Horizon Therapeutics plc to Release First-Quarter 2023 Financial Results on May 3, 2023

Rhea-AI Summary

Horizon Therapeutics plc (NASDAQ: HZNP) will release its first-quarter 2023 financial results on May 3, 2023, before the U.S. markets open. Due to the ongoing acquisition by Amgen, no conference call will be held to discuss these results. The earnings press release will be available on the company's Investor Relations page.

Horizon focuses on developing medicines for rare, autoimmune, and severe inflammatory diseases. The company emphasizes the importance of science and compassion in transforming patient lives. For further details on their mission and pipeline, visit their website.

Positive

• Horizon is focused on critical medical needs in rare diseases.
• Company emphasizes a science-driven approach to patient care.

Negative

• Absence of a conference call could limit investor insights into financial results due to Amgen acquisition.

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its first-quarter 2023 financial results on Wednesday, May 3, 2023, prior to the open of the U.S. financial markets.

With the pending acquisition by Amgen Inc. and applicable securities laws, Horizon will not be hosting a conference call to discuss its financial results. The earnings press release will be publicly available on the Investor Relations page of its website at https://ir.horizontherapeutics.com.

About Horizon

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230414005015/en/

Investor Relations:

Tina Ventura

Senior Vice President, Chief Investor Relations Officer

Investor-relations@horizontherapeutics.com

U.S. Media:

Geoff Curtis

Executive Vice President, Corporate Affairs & Chief Communication Officer

media@horizontherapeutics.com

Ireland Media:

Eimear Rigby

media@horizontherapeutics.com

Source: Horizon Therapeutics plc

FAQ

What date will Horizon Therapeutics release its first-quarter 2023 financial results?

Horizon Therapeutics will release its first-quarter 2023 financial results on May 3, 2023.

Will there be a conference call for Horizon's first-quarter results?

No, Horizon Therapeutics will not host a conference call to discuss its financial results due to its pending acquisition by Amgen.

Where can I find Horizon Therapeutics' earnings press release?

The earnings press release for Horizon Therapeutics will be available on their Investor Relations page.